EGFR and non-small cell lung carcinoma: In the post-hoc analysis of the LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 trials, the second-generation EGFRi afatinib achieved 100% ORR and 14.7 months median PFS for 8 patients with S768I mutant NSCLC leading to FDA approval of this drug for NSCLC patients with EGFR S768I mutations [9].